Home

A new approach to
calcification disorders

Home

SANIFIT

Sanifit is a biopharmaceutical company focused on treatments for calcification disorders, with SNF472 as lead compound. The company was founded in 2007 as a spin-off from the University of the Balearic Islands (Spain). SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease population undergoing haemodialysis.

Sanifit has completed phase Ia studies with healthy volunteers and a phase Ib/IIa study with haemodialysis patients. After a series C funding round of $41.3M (€36.6M), Sanifit will start a phase IIb study in ESRD and extend the orphan program in calciphylaxis into phase II/III clinical trials.

ABOUT US

PROJECT SUPPORTED BY

OVERVIEW PIPELINE

THERAPEUTIC PIPELINE

OTC PIPELINE

LATEST NEWS

Your name (required)

Phone (required)

Company

E-mail (required)

Comments

CONTACT

Sanifit
ParcBIT – Ctra Valldemossa km7.4
Building Europa, 2nd floor
07121 Palma de Mallorca
Illes Balears (Spain)

 +34 971 439 925

 info@sanifit.com